Juniper Publishers: Conservative Management of Young Patients with Early Stage Endometrial Cancer
JUNIPER PUBLISHERS- JOURNAL OF GYNECOLOGY AND WOMEN’S
HEALTH
Journal of Gynecology and Women’s Health-Juniper
Publishers
Authored by Georgios Androutsopoulos*
Endometrial cancer (EC) represents the fifth most
common malignancy in women worldwide, after breast, colorectal, lung and
cervical cancer [1,2].
The disease is more common in developed countries (Northern America and
Northern and Western Europe), but the mortality rate is significantly
higher in the developing ones (Northern Africa and Melanesia) [1,2]. It mainly affects postmenopausal women and abnormal uterine bleeding remains the most common symptom [3-14]. However, up to 14% of cases are premenopausal and almost 4% of patients are younger than 40 years [3-16].
Based on the recent recommendations and guidelines,
systematic surgical staging represents the primary therapeutic approach
in all patients with EC as offers various diagnostic, prognostic and
therapeutic benefits in them [3-10,12,17-20].
However, the extent of this procedure should be carefully
individualized according to the disease stage, the patient’s performance
status and the desire of fertility preservation [5,8,10,12,13,19,20].
In this light, conservative management should be
offered in well selected young patients with early stage disease and
strong desire for fertility sparing treatment [5,8,11,13,21-24]. Only patients with FIGO stage IA, grade 1 and type I (endometrioid) EC, are eligible for this approach [5,8,11,13,15,25].
Moreover, they should have strong desire for fertility preservation, no
contraindications for medical treatment and informed consent about
conservative management [5,8,11,13].
Patients should be informed that conservative
management is a non-standard treatment approach and they should also be
able to accept a very close follow-up during and after fertility sparing
treatment [5,8,11,13,21,24].
Furthermore, they should be carefully counselled regarding risks for
recurrence, anticipated future fertility and pregnancy issues [5,8,11,13,21-24].
Additionally, they should be aware about the need of systematic
surgical staging in case of treatment failure or after childbearing and
be referred to specialised oncologic centres [5,8,11,13,21,22,24].
To begin with, a proper endometrial specimen should
be taken from all patients either with office endometrial biopsy,
hysteroscopy or dilatation and curettage [5,8,11,26-31].
Nevertheless, dilatation and curettage provides better specimens
compared with office endometrial biopsy and it is preferable [5,8, 26,27,29-31].
An expert pathologist should assess the endometrial specimen, in order
to provide an accurate diagnosis of the grade and the type of EC [5,8,11,13,29].
Moreover, hormone receptor status (estrogen, progesterone) and
expression of molecular prognostic markers (p53, Ki-67, HE-4) should
also be evaluated in order to identify tumors with aggressive or
potentially aggressive biologic behavior, where the conservative
management is contraindicated [5,8,11,13,15,32].
The depth of myometrial invasion and the
identification of extrauterine spread (ovarian metastases,
retroperitoneal lymph nodes, omental disease) should be evaluated with
either magnetic resonance imaging (MRI), ultrasound and/or computerized
tomography (CT) [5,8,11,13,29,33-35].
Among them, magnetic resonance imaging assess better the depth of
myometrial invasion, when compared with ultrasound and computerized
tomography and it is usually preferred [5,8,11,13,29,33-35].
Apart from that, useful data regarding disease stage might be obtained
with laparoscopy, although it still remains an optional evaluation
method [5,11,13].
The conservative management of young patients with
FIGO stage IA, grade 1 and type I (endometrioid) EC, is mainly based on
oral progestins [5,8,11,13,36-38]. In daily practice, medroxyprogesterone acetate and megestrol acetate, are the most common used progestin regimens [5,8,11,13,36-38]. The average daily dosage of medroxyprogesterone acetate is 400-600 mg, while that of megestrol acetate is 160-320 mg [5,8,13,39].
The treatment with oral progestins usually lasts 6 months, although in
the past many patients treated for longer periods of time [5,8,11,13,29,39-41].
Recently, the combined administration of GnRH-analogues with
intrauterine devices releasing levonorgestrel, showed promising results
and represents an alternative treatment approach [8,13,29,37,42].
During the conservative management, endometrial
sampling (dilatation and curettage or hysteroscopy) should be performed
every 3 months, in order to assess the response to treatment [5 8 11 13 29 37 43].
At the end of 6-month period with oral progestins administration, the
overall response to treatment should be re-evaluated with MRI [5,8,11,13,29,34-43].
If there is no response, systematic surgical staging should be
performed as there is no evidence of prolonged (more than 6 months)
hormonal treatment to achieve late response [3-13,17-20,29,40,41].
In case of complete response to the conservative
treatment, the patient should be referred to a fertility centre and
offered an assisted conception protocol [5,8,11,13,44-47]. Interestingly, there is evidence that pregnancy substantially reduces the risk of disease recurrence [5,8,11,13,37,44].
However in case that the pregnancy is not immediately desirable, then
the treatment with oral progestins should be continued and the patients
should be reassessed in 6 months intervals [5,8,11,13,29,37,44].
According to recent data, the overall response to the conservative management of EC patients is about 75% [5,8,11,13,23,29,44-48].
However, all these patients who treated with oral progestins, should
have systematic surgical staging after childbearing as the overall
recurrence rate ranges between 30% and 40% [5,8,11,13,23,29,44,48].
In conclusion, only well selected young patients with
FIGO stage IA, grade 1 and type I (endometrioid) EC are eligible for
conservative management with oral progestins [5,8,11,13,15,25]. Although this is a promising approach, it cannot be used as a standard treatment [3-10,12,13,17,18].
Consequently, patients should be thoroughly counseled and informed
about the feasibility of that innovative treatment approach and the
necessity of systematic surgical staging in case of no response,
recurrence or after childbearing [5,8,11,13,23,44,48].
For more articles on Gynecology and Women’s
Health please click on: https://juniperpublishers.com/jgwh/
Comments
Post a Comment